REGENERON PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 892.5 USD | +1.05% |
|
-0.85% | +1.62% |
| Apr. 26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
| Apr. 26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
Presentation Operator MessageOperator (Operator)Welcome to the Regeneron Pharmaceuticals' Four...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
892.5
USD
Average target price
1,038
USD
Spread / Average Target
+16.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.62% | 96.29B | |
| -2.63% | 102B | |
| +1.98% | 22.18B | |
| -16.67% | 21.2B | |
| -9.86% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B | |
| +305.27% | 8.32B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Transcript : Regeneron Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 02, 2024
